Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting
Rhea-AI Summary
Artiva Biotherapeutics announced new data presentations for their AlloNK® cell therapy at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in New Orleans this May.
Key highlights:
- New longer-term Phase 1/2 data shows promising results for AlloNK® combined with rituximab in treating relapsed/refractory B-cell non-Hodgkin lymphoma
- Treatment demonstrated prolonged response duration, deep B-cell depletion, and well-tolerated safety profile
- Results support AlloNK's potential for treating B-cell driven diseases in community settings
Two poster presentations are scheduled:
- May 13: AlloNK® Cell Therapy ± Rituximab in Patients with Non-Hodgkin Lymphoma
- May 15: AlloNK manufacturing process scalability and consistency
The presentations highlight Artiva's progress in developing accessible cell therapies for autoimmune diseases and cancers. Abstracts are available on the ASGCT website, with poster copies to be shared on Artiva's website after the presentations.
Positive
- Longer-term Phase 1/2 data shows prolonged duration of response for AlloNK therapy
- Deep B-cell depletion demonstrated in clinical results
- Well-tolerated safety profile reported for AlloNK + rituximab combination
- Manufacturing process shows scalability and consistency
- Potential application in both oncology and autoimmune diseases
Negative
- None.
Insights
Artiva's positive Phase 1/2 data for AlloNK in lymphoma demonstrates clinical promise and manufacturing scalability, boosting their competitive position.
The new longer-term Phase 1/2 data for Artiva's AlloNK® (AB-101) represents meaningful clinical progress for this emerging cell therapy. The reported prolonged duration of response and deep B-cell depletion in relapsed/refractory B-cell non-Hodgkin lymphoma patients are encouraging efficacy signals. What's particularly noteworthy is the combination with rituximab, which leverages a well-established therapy while potentially enhancing its efficacy through antibody-dependent cellular cytotoxicity mechanisms.
The well-tolerated safety profile addresses a critical hurdle for cell therapies, which have historically faced challenges with toxicities. Moreover, the explicit mention of potential application "in a community setting" suggests Artiva is positioning AlloNK as more accessible than current cellular therapies that require specialized centers.
The second presentation on manufacturing scalability and consistency is equally significant. Manufacturing complexities have been a fundamental limitation for cell therapies, restricting commercial viability and increasing costs. Evidence of a robust, scalable process could differentiate Artiva's platform in the competitive cell therapy landscape.
These presentations represent incremental but important progress for a clinical-stage biotech developing next-generation cell therapies. The allogeneic ("off-the-shelf") approach potentially offers advantages over autologous therapies in terms of manufacturing efficiency and treatment accessibility for lymphoma patients.
Artiva's AlloNK therapy shows promising efficacy and safety in lymphoma with potentially broader accessibility than current cellular therapies.
The clinical profile emerging for AlloNK in relapsed/refractory B-cell non-Hodgkin lymphoma addresses several key limitations of current treatments. The prolonged duration of response is particularly valuable in the relapsed setting, where response durability typically diminishes with each subsequent therapy. Deep B-cell depletion indicates robust on-target activity against malignant B-cells, essential for disease control.
The combination with rituximab represents a mechanistically sound approach. NK cells naturally enhance rituximab's efficacy through ADCC (antibody-dependent cellular cytotoxicity), potentially providing synergistic effects without requiring complex genetic engineering like CAR-T approaches. This could translate to both improved efficacy and a more manageable safety profile.
The well-tolerated safety profile supporting potential use "in a community setting" could significantly expand patient access compared to current cellular therapies that require specialized centers due to toxicity management concerns. Most CAR-T and other cellular therapies necessitate hospitalization and specialized monitoring for cytokine release syndrome - a requirement that substantially limits their broad application.
The manufacturing presentations addressing scalability and consistency tackle another fundamental barrier to cellular therapy adoption. Consistent product quality is essential for predictable clinical outcomes, and manufacturing reliability directly impacts therapeutic accessibility.
These data points collectively suggest AlloNK could potentially offer advantages in efficacy, safety, and accessibility - three critical dimensions for advancing lymphoma treatment.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Prolonged duration of response, deep B-cell depletion, and well-tolerated safety profile support the potential of AlloNK® + rituximab for the treatment of B-cell driven diseases in a community setting
Additional poster presentation to feature scalability and consistency of AlloNK manufacturing process
SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, announced today that the Company will have a poster presentation on new longer-term Phase 1/2 data for AlloNK® (also known as AB-101) in patients with relapsed/refractory B-cell non-Hodgkin lymphoma at the upcoming American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting taking place May 13-17, 2025, in New Orleans, Louisiana. These results demonstrate prolonged duration of response, deep B-cell depletion and a well-tolerated safety profile of AlloNK in combination with rituximab.
In addition, the Company will have a poster presentation featuring the scalability and consistency of the AlloNK manufacturing process.
Details of the presentations are as follows:
Abstract 858 – AlloNK® Cell Therapy ± Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Date/Time: May 13, 2025, 6:00 p.m. – 7:30 p.m. CT
Session Title: Poster Reception
Location: Poster Hall I2
Abstract 1765 – AlloNK: A Scalable and Consistent NK Cell Therapy in Development for Treatment of Oncology and Autoimmune Diseases
Date/Time: May 15, 2025, 5:30 p.m. – 7:00 p.m. CT
Session Title: Poster Reception
Location: Poster Hall I2
Abstracts are currently available on the ASGCT website. Following the presentations, copies will be available on the "Scientific Posters & Publications" section of the “Events & Presentation” page on the Company's website.
About Artiva Biotherapeutics
Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Artiva’s lead program, AlloNK®, is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. AlloNK® is currently in clinical trials for treatment of systemic lupus erythematosus, for patients with or without lupus nephritis, and in an investigator-initiated basket trial in multiple autoimmune indications. Artiva’s pipeline also includes CAR-NK candidates targeting both solid and hematologic cancers. Artiva was founded in 2019 as a spin out of GC Cell, formerly GC Lab Cell Corporation, a leading healthcare company in the Republic of Korea, pursuant to a strategic partnership granting Artiva exclusive worldwide rights (excluding Asia, Australia and New Zealand) to GC Cell’s NK cell manufacturing technology and programs.
Artiva is headquartered in San Diego, California. For more information, please visit www.artivabio.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding Artiva Biotherapeutics, Inc.’s (the “Company”) participation in the ASGCT 28th Annual Meeting; the content of the Company’s presentations; the potential benefits, accessibility, effectiveness and safety of AlloNK® + rituximab for the treatment of B-cell driven diseases; and the Company’s expectations regarding timing and availability of data from the Company’s clinical trials. These forward-looking statements are based on the beliefs of the management of the Company as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause the Company’s actual results to differ from current expectations are discussed in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
Investors: Neha Krishnamohan, Artiva Biotherapeutics, ir@artivabio.com
Media: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com, +1.858.344.8091
Source: Artiva Biotherapeutics, Inc.
